

CITATION REPORT

List of articles citing

Aspirin, hydroxychloroquine, and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis

DOI: 10.1002/art.1780331102

Arthritis and Rheumatism, 1990, 33, 1611-9.

Source: <https://exaly.com/paper-pdf/21399481/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
106	Therapy for rheumatoid arthritis: combinations of disease-modifying drugs and new paradigms of treatment. 1991 , 21, 21-34		30
105	Prognostic staging for therapy of rheumatoid arthritis. 1991 , 21, 40-3		10
104	Pharmacological management of juvenile rheumatoid arthritis. 1992 , 43, 849-63		7
103	Synthesis of methotrexate-dimyristoylphosphatidylethanolamine analogs and characterization of methotrexate release in vitro. 1992 , 85, 189-197		13
102	Liver enzyme levels in arthritis patients treated with long-term bolus methotrexate. <i>Arthritis and Rheumatism</i> , 1992 , 35, 126-8		8
101	Reply. <i>Arthritis and Rheumatism</i> , 1992 , 35, 127-128		2
100	Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. <i>Arthritis and Rheumatism</i> , 1992 , 35, 849-56		91
99	Comparing the strengths and weaknesses of observational and experimental studies using a postmarketing surveillance study as a prototypic example. 1993 , 23, 57-61		2
98	The relative toxicity of alternative therapies for rheumatoid arthritis: implications for the therapeutic progression. 1993 , 23, 68-73		13
97	Methotrexate in rheumatoid arthritis: can current knowledge and experience justify its use as a first-line disease-modifying agent?. 1993 , 69, 775-80		4
96	Immunosuppressive drugs and their complications. 1994 , 32, 66-70		4
95	Chloroquine reduces the bioavailability of methotrexate in patients with rheumatoid arthritis. A possible mechanism of reduced hepatotoxicity. <i>Arthritis and Rheumatism</i> , 1994 , 37, 830-3		34
94	Suggested guidelines for monitoring liver toxicity in rheumatoid arthritis patients treated with methotrexate: comment on the article by Kremer et al. <i>Arthritis and Rheumatism</i> , 1994 , 37, 1829-30		7
93	Reply. <i>Arthritis and Rheumatism</i> , 1994 , 37, 1830-1830		
92	Combination therapy with methotrexate and chloroquine in rheumatoid arthritis. A multicenter randomized placebo-controlled trial. 1994 , 23, 231-6		47
91	A risk-benefit assessment of slow-acting antirheumatic drugs in rheumatoid arthritis. 1994 , 11, 21-36		4
90	Methotrexate in rheumatoid arthritis. An update. 1994 , 47, 25-50		117

89	Current concepts in psoriatic arthritis. 1994 , 189 Suppl 2, 35-41	5
88	Practical Clinical Pharmacology and Drug Interactions of Low-Dose Methotrexate Therapy in Rheumatoid Arthritis. 1995 , XXXIV, 20-25	22
87	Practical Clinical Pharmacology and Drug Interactions of Low-Dose Methotrexate Therapy in Rheumatoid Arthritis. 1995 , XXXIV, 20-25	21
86	Hazards of low dose methotrexate. 1995 , 25, 670-3	12
85	Antimalarial Drugs. 1995 , 4, 219-234	5
84	Slow-acting antirheumatic drugs. Drug interactions of clinical significance. 1995 , 13, 25-30	3
83	Biochemical characterization of ADP-ribose polymer metabolism in SLE. 1996 , 5, 14-21	115
82	Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis. 1996 , 128, 698-700	36
81	Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. 1996 , 30, 194-210	133
80	Clinical Significance of Drug Interactions with Antirheumatic Agents. 1996 , 5, 205-213	2
79	The Use of Slower-Acting (Class III) Symptom-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. 1996 , 5, 309-325	
78	Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. 1996 , 5, 16-22	143
77	The use of antimalarials in combination with other disease modifying agents in rheumatoid arthritis—the French Experience. 1996 , 5, 45-49	1
76	The role of anti-malarials in rheumatoid arthritis —the American experience. 1996 , 5, 41-44	13
75	The use of antimalarials in combination with other disease modifying agents in RA —the British experience. 1996 , 5, 50-58	6
74	Review article: methotrexate in gastroenterology—dangerous villain or simply misunderstood?. 1996 , 10, 851-8	17
73	Effect of age on the efficacy and tolerance of methotrexate in rheumatoid arthritis. 1996 , 35, 453-7	28
72	Antimalarial drugs in the treatment of rheumatological diseases. 1997 , 36, 799-805	120

71	The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases. 1997 , 36, 1196-204	68
70	Extra-articular complications of rheumatoid arthritis: a review of recent literature. 1997 , 7, 153-163	
69	Methotrexate hepatotoxicity. 1997 , 23, 883-915	94
68	Extra-articular complications of rheumatoid arthritis: a review of recent literature. 1997 , 7, 153-163	
67	Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. 1998 , 27, 277-92	172
66	Clinically important drug interactions with disease-modifying antirheumatic drugs. 1998 , 13, 281-9	7
65	Interleukin-1beta (IL-1beta) inhibition: a possible mechanism for the anti-inflammatory potency of liposomally conjugated methotrexate formulations in arthritis. 1999 , 128, 234-40	14
64	Efficacy and safety of a combination therapy of methotrexate, chloroquine and cyclophosphamide in patients with refractory rheumatoid arthritis: results of an observational study with matched-pair analysis. <i>Clinical Rheumatology</i> , 1999 , 18, 145-51	3.9 11
63	Pharmacotherapeutic combination strategies with disease-modifying antirheumatic drugs in established rheumatoid arthritis. 1999 , 13, 689-700	5
62	[Treatment of rheumatoid polyarthritis: evolution of concepts and strategies]. 1999 , 20, 171-8	13
61	Methotrexate nodulosis. 1999 , 26, 460-4	10
60	Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term?. 2000 , 39, 1102-9	50
59	Questions answered and a \$1 million question raised concerning lupus erythematosus tumidus: is routine laboratory surveillance testing during treatment with hydroxychloroquine for skin disease really necessary. 2000 , 136, 1044-9	21
58	Antimalarials. 2001 , 19, 147-60, ix	55
57	Combination therapy for autoimmune diseases: the rheumatoid arthritis model. 2001 , 23, 5-26	7
56	Antimalarials. 2001 , 14, 143-153	1
55	Efficiency of combined methotrexate/chloroquine therapy in adjuvant-induced arthritis. 2005 , 19, 479-89	14
54	Hydroxychloroquine does not decrease serum methotrexate concentrations in children with juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2005 , 52, 1621-2	4

53	Optimal use of antimalarials in treating cutaneous lupus erythematosus. 2005 , 6, 1-11	29
52	[Antimalarials: an update in rheumatic diseases]. 2006 , 2, 190-201	8
51	Hepatotoxicity of chemotherapy. 2006 , 33, 50-67	176
50	Comparative study of the pharmacokinetics of MTX in juvenile idiopathic arthritis patients receiving long-term MTX monotherapy or MTX plus chloroquine. 2007 , 32, 579-84	2
49	Salubrious effect of Kalpaamruthaa, a modified indigenous preparation in adjuvant-induced arthritis in rats--a biochemical approach. 2008 , 173, 148-58	25
48	Anti-inflammatory effect of petroleum ether extract of Vitex negundo leaves in rat models of acute and subacute inflammation. 2009 , 47, 335-339	4
47	Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. 2010 , 37, 1416-21	67
46	Medical and surgical therapy of inflammatory bowel disease in the elderly - prospects and complications. 2011 , 5, 177-88	41
45	Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). 2011 , CD008872	35
44	Effect of three lipophilic methotrexate derivatives upon mediator release by lipopolysaccharide-stimulated rat peritoneal macrophages. 1994 , 46, 291-5	9
43	Safety of nonsteroidal antiinflammatory drugs and/or paracetamol in people receiving methotrexate for inflammatory arthritis: a Cochrane systematic review. 2012 , 90, 62-73	33
42	Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. 2012 , 51, 1416-25	43
41	Lupeol, a triterpenoid isolated from Calotropis gigantea latex ameliorates the primary and secondary complications of FCA induced adjuvant disease in experimental rats. 2012 , 20, 27-37	19
40	Aspirin antagonizes the cytotoxic effect of methotrexate in lung cancer cells. 2013 , 30, 1497-505	14
39	Anti-inflammatory activity and mechanism of a lipid extract from hard-shelled mussel (Mytilus coruscus) on chronic arthritis in rats. 2014 , 12, 568-88	22
38	Australian and New Zealand evidence-based recommendations for pain management by pharmacotherapy in adult patients with inflammatory arthritis. 2014 , 17, 738-48	2
37	Protective effects of Balanites aegyptiaca extract, Melatonin and Ursodeoxycholic acid against hepatotoxicity induced by Methotrexate in male rats. 2017 , 10, 557-565	15
36	Novel drug delivery of dual acting prodrugs of hydroxychloroquine with aryl acetic acid NSAIDs: Design, kinetics and pharmacological study. 2017 , 7, 709-730	14

35	Interaction Between Low-Dose Methotrexate and Nonsteroidal Anti-inflammatory Drugs, Penicillins, and Proton Pump Inhibitors. 2017 , 51, 163-178	19
34	Spirulina ameliorates methotrexate hepatotoxicity via antioxidant, immune stimulation, and proinflammatory cytokines and apoptotic proteins modulation. 2018 , 196, 9-17	47
33	Protective Effects of Magnesium Glycyrrhizinate on Methotrexate-Induced Hepatotoxicity and Intestinal Toxicity May Be by Reducing COX-2. 2019 , 10, 119	15
32	PLK1 (polo like kinase 1)-dependent autophagy facilitates gefitinib-induced hepatotoxicity by degrading COX6A1 (cytochrome c oxidase subunit 6A1). 2021 , 17, 3221-3237	11
31	Review article: COVID-19 and liver disease-what we know on 1st May 2020. 2020 , 52, 267-275	92
30	İçucuklarda COVID-19 ve Karaciğer. 2021 , 9, 45-49	
29	Liver and COVID-19: possible mechanisms of damage. 2021 , 93, 427-430	2
28	Alcohol-Related Liver Disease in the Covid-19 Era: Position Paper of the Italian Society on Alcohol (SIA). 2021 , 1	0
27	Juvenile Rheumatoid Arthritis. 1993 , 231-359	6
26	Hepatitis due to non-steroidal anti-inflammatory drugs (NSAIDs). 1992 , 211-222	3
25	PHARMACOLOGY AND DRUG THERAPY. 2005 , 76-141	9
24	HEPATOTOXICITY OF CHEMOTHERAPEUTIC AND ONCOLOGIC AGENTS. 1995 , 24, 969-990	44
23	ANTIMALARIAL AGENTS AND LUPUS. 1994 , 20, 243-263	96
22	Methotrexate in rheumatoid arthritis. 2000 , 83-108	
21	Combination therapy for autoimmune diseases: the rheumatoid arthritis model. 2002 , 5-26	
20	Methotrexate. 2005 , 175-197	
19	THE NEED FOR AGGRESSIVE THERAPY OF RHEUMATOID ARTHRITIS. 1993 , 19, 153-161	10
18	METHOTREXATE: ADVERSE REACTIONS AND MAJOR TOXICITIES. 1994 , 20, 513-528	58

17	REFRACTORY RHEUMATOID ARTHRITIS. 1995 , 21, 1-18		9
16	Disease-modifying anti-rheumatic drugs. 2005 , 511-544		
15	Data_Sheet_1.ZIP. 2019 ,		
14	Data_Sheet_2.ZIP. 2019 ,		
13	Data_Sheet_3.ZIP. 2019 ,		
12	Data_Sheet_4.ZIP. 2019 ,		
11	Data_Sheet_5.PDF. 2019 ,		
10	Data_Sheet_6.PDF. 2019 ,		
9	Table_1.XLSX. 2019 ,		
8	Table_2.XLSX. 2019 ,		
7	Table_3.XLSX. 2019 ,		
6	Table_4.XLSX. 2019 ,		
5	Table_5.XLSX. 2019 ,		
4	Table_6.XLSX. 2019 ,		
3	Long-term methotrexate in refractory rheumatoid arthritis; concurrent use of prednisone possibly improves drug-survival. <i>Clinical Rheumatology</i> , 1994 , 13, 317-8	3.9	1
2	REVIEW OF RHEUMATOID ARTHRITIS. 1993 , 13, 273-289		2
1	THE EFFECTIVENESS OF SHEAR WAVE ELASTOGRAPHY IN THE ASSESSMENT OF LIVER DAMAGE IN PATIENTS WITH POST-COVID SYNDROME. 2022 , 99-113		0